97 related articles for article (PubMed ID: 21627359)
21. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM; Rischin D; Fisher R; Cao H; Kwok K; Truong D; McArthur GA; Young RJ; Giaccia A; Peters L; Le QT
Clin Cancer Res; 2012 Jan; 18(1):301-7. PubMed ID: 22096023
[TBL] [Abstract][Full Text] [Related]
23. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
24. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
[TBL] [Abstract][Full Text] [Related]
25. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
[TBL] [Abstract][Full Text] [Related]
26. [Association of the expression of p53 and p16INK4A with the clinical and morphological characteristicsof patients with head and neck squamous cell cancer].
Stukan AI; Chukhray OY; Porkhanov VA; Bodnya VN
Arkh Patol; 2019; 81(3):12-18. PubMed ID: 31317926
[TBL] [Abstract][Full Text] [Related]
27. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
[TBL] [Abstract][Full Text] [Related]
28. Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma.
Lundberg M; Leivo I; Saarilahti K; Mäkitie AA; Mattila PS
Acta Otolaryngol; 2012 Sep; 132(9):1006-12. PubMed ID: 22667340
[TBL] [Abstract][Full Text] [Related]
29. Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.
Yildirim M; Müller von der Grün J; Winkelmann R; Fokas E; Rödel F; Ackermann H; Rödel C; Balermpas P
Strahlenther Onkol; 2017 Apr; 193(4):305-314. PubMed ID: 28144684
[TBL] [Abstract][Full Text] [Related]
30. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
31. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
[TBL] [Abstract][Full Text] [Related]
32. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
34. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Kawasaki Y; Okumura H; Uchikado Y; Kita Y; Sasaki K; Owaki T; Ishigami S; Natsugoe S
Ann Surg Oncol; 2014 Jul; 21(7):2347-52. PubMed ID: 24599410
[TBL] [Abstract][Full Text] [Related]
35. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
[TBL] [Abstract][Full Text] [Related]
36. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
[TBL] [Abstract][Full Text] [Related]
37. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
Ishiguro R; Fujii M; Yamashita T; Tashiro M; Tomita T; Ogawa K; Kameyama K
Anticancer Res; 2003; 23(6D):5213-20. PubMed ID: 14981992
[TBL] [Abstract][Full Text] [Related]
38. Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Mücke T; Konen M; Wagenpfeil S; Kesting MR; Wolff KD; Hölzle F
Ann Surg Oncol; 2011 Oct; 18(10):2739-47. PubMed ID: 21424882
[TBL] [Abstract][Full Text] [Related]
39. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
[TBL] [Abstract][Full Text] [Related]
40. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
